- Home
- CNS vs AXSM Comparison
CNS vs AXSM Comparison
Compare CNS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNS
- AXSM
- Stock Information
- Founded
- CNS 1986
- AXSM 2012
- Country
- CNS United States
- AXSM United States
- Employees
- CNS N/A
- AXSM N/A
- Industry
- CNS Investment Managers
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CNS Finance
- AXSM Health Care
- Exchange
- CNS Nasdaq
- AXSM Nasdaq
- Market Cap
- CNS 4.4B
- AXSM 5.1B
- IPO Year
- CNS 2004
- AXSM 2015
- Fundamental
- Price
- CNS $80.32
- AXSM $107.76
- Analyst Decision
- CNS Hold
- AXSM Strong Buy
- Analyst Count
- CNS 3
- AXSM 15
- Target Price
- CNS $81.00
- AXSM $170.20
- AVG Volume (30 Days)
- CNS 178.1K
- AXSM 655.3K
- Earning Date
- CNS 04-16-2025
- AXSM 05-05-2025
- Dividend Yield
- CNS 3.10%
- AXSM N/A
- EPS Growth
- CNS 18.98
- AXSM N/A
- EPS
- CNS 3.06
- AXSM N/A
- Revenue
- CNS $529,174,000.00
- AXSM $432,157,000.00
- Revenue This Year
- CNS $5.81
- AXSM $63.52
- Revenue Next Year
- CNS $12.38
- AXSM $63.32
- P/E Ratio
- CNS $26.15
- AXSM N/A
- Revenue Growth
- CNS 8.82
- AXSM 72.16
- 52 Week Low
- CNS $67.09
- AXSM $64.11
- 52 Week High
- CNS $110.67
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- CNS 59.18
- AXSM 46.37
- Support Level
- CNS $76.09
- AXSM $103.15
- Resistance Level
- CNS $79.25
- AXSM $120.00
- Average True Range (ATR)
- CNS 2.21
- AXSM 3.51
- MACD
- CNS 0.73
- AXSM 0.66
- Stochastic Oscillator
- CNS 93.96
- AXSM 29.45
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.